论文部分内容阅读
目的观察依达拉奉联合尤瑞克林治疗急性脑梗死的临床效果。方法选取2012年12月-2014年12月急性脑梗死患者100例,随机分为试验组和对照组各50例,试验组给予依达拉奉与尤瑞克林联合治疗,对照组仅给予依达拉奉治疗。对比2组治疗后神经功能缺损评分等的差异性。结果试验组总有效率42.00%明显优于对照组72.00%(P<0.05)。2组治疗后神经功能缺损评分较之治疗前均明显改善,且试验组明显优于对照组,差异均有统计学意义(P<0.05)。结论临床给予急性脑梗死患者实施依达拉奉联合尤瑞克林治疗,可以明显提高脑梗死患者治疗的效果,改善患者的生活质量,安全有效,值得在临床应用和推广。
Objective To observe the clinical effect of edaravone combined with noreclin in the treatment of acute cerebral infarction. Methods A total of 100 acute cerebral infarction patients from December 2012 to December 2014 were randomly divided into experimental group and control group (n = 50). The experimental group was treated with edaravone and nociceptin, while the control group received only Da Vinci treatment. The difference between the two groups after treatment of neurological deficit score and so on. Results The total effective rate of 42.00% in the experimental group was significantly better than that in the control group (72.00%, P <0.05). The scores of neurological deficits in both groups were significantly improved after treatment, and the experimental group was significantly better than the control group (P <0.05). Conclusion The clinical application of edaravone combined with erilachlor in patients with acute cerebral infarction can significantly improve the therapeutic effect of patients with cerebral infarction and improve the quality of life of patients, which is safe and effective, which is worthy of clinical application and promotion.